Press Release 2007 JUL 10 ( PDF - 104.6 kb - Selexis

lunchlexicographerBiotechnology

Dec 1, 2012 (4 years and 10 months ago)

294 views

CONFIDENTIAL
SUBJECT TO CONTRACT
YOUR PARTNER FOR CELL LINE
DEVELOPMENT
June 12, 2007
Page 1 of 1
18, chemin des Aulx

1228 Plan-les-Ouates
Geneva

Switzerland
T +41 (0)22 308 9360
F +41 (0)22 308 9361
info@selexis.com
www.selexis.com
Selexis Signs Commercial License Agreement with GANYMED Pharmaceuticals
GANYMED Pharmaceuticals AG Enters into License Agreement with Selexis SA to Use
SURE Technology Platform
SM
for Mammalian Cell Line Development and for Large Scale Production of
Ganymed’s First Monoclonal Antibody Drug.
GENEVA,
SWITZERLAND,

July
11,
2007/PRNewswire/
--
Selexis
SA,
a
Swiss-based
biotechnology
company
offering
technologies
and
services
to
enable
significantly
improved
drug
discovery,
development,
and
cGMP
production,
announced
today
that
it
has
signed
a
commercial
license
agreement
with
GANYMED
Pharmaceuticals
AG,
a
privately
held
cancer
antibody
company
of
Mainz,
Germany,
for
use
of
the
Selexis
technology
for
large
scale
production
of
GANYMED’s

lead
antibodies.
Ganymed’s
antibodies
have
a
unique
specificity
for
a
variety
of
solid cancers with high medical need and large market potential.
This
commercial
license
agreement
allows
GANYMED
to
use
a
high
performance
cell
line,
developed
by
GANYMED
scientists
using
the
Selexis
SURE
Cell
Line
Development
platform,
for
the
clinical
and
commercial
production of a number of products.
“We
are
thrilled
to
be
extending
and
possibly
intensifying
our
relationship
with
GANYMED
Pharmaceuticals.
I
am
also
very
pleased
that
our
technology
platform
is
supporting
GANYMEDs’
potent
therapeutic
program”
said
Dr.
Igor Fisch, CEO of Selexis.
About Selexis:
Selexis
is
a
privately
held
biotechnology
company
dedicated
to
the
development
of
innovative
technologies
and
expert
services
that
enables
significant
improvements
in
the
time,
effort
and
costs
required
to
develop
and
maintain
high
performance
mammalian
cell
lines
for
use
in
the
expression
of
pharmaceutically
relevant
proteins
(i.e.
targets,
MABs,
rProteins).
The
company's
core
intellectual
property
portfolio
is
based
on
the
discovery
and
application
of
enabling
genetic
elements
that
control
the
dynamic
organization
of
chromatin
within
all
mammalian
cells.
Application
of
the
Selexis
Genetic
Elements

using
the
SURE
Cell
Line
Development

process
has
enabled
the
rapid
development
of
high
performance
cell
lines
for
a
number
of
pharmaceuticaly
important
programs.
The
Selexis
core
technologies
also
enable
applications
in
the
emerging
biotechnology
area
of
gene
and
stem cell therapy.
Selexis Genetic Elements™ and SURE Cell Line Development
SM
are trademarks of Selexis SA.
MORE INFORMATION:
EUROPE
Igor Fisch, Ph.D.
41 (0)22 308 93 60
Igor.fisch@selexis.com
UNITED STATES
Andrew F. Sandford
(617) 595-5769
andrew.sanford@selexis.com